Virtual Event: Functional Food Proteins with Microbial Expression Systems

Watch the Event

A recording of the Virtual Event, Functional Food Proteins with Microbial Expression Systems, is available here.

 

Foundry Services for Functional Proteins

On June 30th, Ginkgo hosted a live virtual event to present our latest strain engineering capabilities for food proteins and enzymes. These capabilities support our offering of R&D services for the nutrition and wellness industry and are relevant for anyone seeking to produce functional protein ingredients with precision fermentation.

Strain Matters: Pichia and Aspergillus

The event featured two of our favorite microbial production hosts, Pichia pastoris and Aspergillus niger. Both of these strains have long been favored for protein and enzyme production because of their high productivity, food-safe regulatory status and ability to grow on low-cost feedstocks.

But not all strains of yeast and fungi can perform at the level required for food ingredient production at scale. A key message of the event was that your strain matters: choosing the correct expression host for your protein product can speed up your development times and decrease your final production costs.

Ginkgo offers proprietary strains of Pichia and Aspergillus that can address many of the common challenges of food protein or enzyme production. Two featured presentations during the event described the relative strengths of each strain and a case study in which the strain delivered for a particular customer’s performance requirements.

Pichia is often preferred as a base strain for its easy engineerability and large genetic toolbox. Andrea Camattari, Senior Director of Organism Engineering, presented a recent project in which Pichia was adapted to produce an iron-binding food protein, using proprietary methanol-free expression systems (20-fold higher expression than methanol based promoters). Several strategies were employed to improve the expression and the localization of the needed cofactors, resulting in a host strain that far exceeded the customer’s production targets.

Aspergillus can produce certain classes of proteins at extraordinarily high titer (120 g/L or higher), but has historically been limited in large-scale fermentations because of its high viscosity. Peter Punt, Distinguished Organism Engineer and Guest Professor at Leiden University, described Ginkgo’s proprietary low-viscosity, proteases knocked-out and “clean” background Aspergillus that can produce food proteins and enzymes in high titer.

Technology Matters: Ginkgo’s Foundry

Strain engineering at Ginkgo, whether in Pichia, Aspergillus, or another host organism, is an integrated process that benefits from the full stack of cell programming technologies available on our foundry platform. Sneha Srikrishnan, Director of Growth, surveyed a range of technological capabilities that we can deploy for a customer’s project.

Metagenomic Protein Discovery: For projects seeking a particular function or enzyme activity, but without a precisely defined sequence, Ginkgo offers a large in-house discovery library of more than 2 billion genes. This library is substantially larger than public repositories and enables the discovery of previously undescribed functional proteins and enzymes.

ML-Guided Protein Engineering: Enzyme Intelligence™ is Ginkgo’s platform for protein engineering employing generative AI and structure-based design. Our protein engineering team is distinguished by the depth of their experience, having delivered dozens of projects across a range of applications, and the large datasets they can access through Ginkgo’s experimental and assay capabilities.

Industry-Leading Automation: Ginkgo has invested almost half a billion dollars in foundry infrastructure, including an expansive robotics platform for automated DNA assembly, transformation, and strain characterization. Data-rich enzyme engineering projects are needed to make the most of data-hungry ML software. High-throughput strategies that can discover rare high-performance variants that can be missed with low-throughput approaches.

Phenotypic Selection with EncapS: The EncapS (Encapsulation and Screening) system allows up to one million strain variants to be characterized in a single campaign. The ultra-high-throughput technology uses microfluidics to package cells in nanoliter-scale droplets, allowing measurement and optimization of secreted protein production. As a screening technique, EncapS can enable strain improvement even without targeted genetic modifications.

Experience Matters: Success-Based Pricing

The depth of Ginkgo’s experience in protein and enzyme production projects gives us a unique confidence in our ability to meet our customers’ performance targets. Alyssa Blaize, Director of Growth, presented our new Success-Based Pricing model as a way for Ginkgo to “put our money where our mouth is” and to allow our customers to directly benefit from that experience.

Projects that are covered by Success-Based Pricing include enzyme discovery, protein engineering and production optimization projects that are determined to have a high probability of success. Ginkgo and our partner work together to set the performance targets for a particular project. If the performance targets aren’t met, the customer pays no R&D fees.

This presentation included more details about the Success-Based Pricing model and a project flowchart highlighting decision points and cost structures at each phase. With Success-Based Pricing, customers are able to lower their technical risk and minimize their financial exposure to the traditional uncertainties of biology R&D.

Optimizing Enzyme Expression and Performance with Zymtronix

Optimizing enzymes for Zymtronix’s cell-free manufacturing platform

Today we are pleased to announce our partnership with Zymtronix, a developer of cell-free process technologies. Together we aim to optimize enzymes used in Zymtronix’s proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals.

Enzymatic biocatalysis is a powerful manufacturing technology that can enable the production of a wide range of chemicals and molecules. Zymtronix’s cell-free platform is designed to solve challenges associated with traditional biocatalysis and seeks to enable the production of a wide range of products with precision and productivity. By partnering with us to build and produce bioengineered market-ready enzymes, Zymtronix anticipates being able to extend its solutions into the pharma, nutrition, agriculture markets, among others.

Zymtronix aims to leverage Ginkgo Enzyme Services to discover, optimize, and produce enzymes

Ginkgo Enzyme Services offers partners end-to-end support for the discovery, optimization, and production of enzymes for diverse applications. Through the partnership, we will leverage our suite of enzyme services to engineer enzymes for Zymtronix’s applications using metagenomic enzyme discovery as well as improve enzyme expression and production host performance.

We’re thrilled to welcome Zymtronix to the platform and support their applications in sustainable ingredients and beyond. We’ve built out our platform to serve a wide variety of enzyme discovery, engineering, optimization and scale up efforts, and we’re so excited for the work to come in this partnership. Zymtronix’s cell-free biomanufacturing platform is pioneering solutions for various industries, and we’re eager to leverage our end-to-end capabilities and help expand its efforts in transforming the way enzymes are used.

“This partnership will greatly accelerate our work of bringing the precision and scalability of cell-free biomanufacturing and sustainable ingredients to market starting with alternatives to animal sources; Ginkgo is uniquely able to support us with both enzyme engineering and strain expression, helping us continue to accelerate commercialization,” said Stéphane Corgié, CEO-CTO and founder, Zymtronix. “We hope to extend this partnership in the future to facilitate the production of multiple end-market products.”

To learn more about Ginkgo Enzyme Services, please visit ginkgobioworks.com/enzyme-services/.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Better Baby Formula with NAMUH

Ginkgo will develop and optimize strains to produce functional oligosaccharides for NAMUH’s infant nutrition products

Today, we are pleased to announce a multi-product collaboration with NAMUH, an infant nutrition company, to develop functional oligosaccharides that are structurally identical to those found in human breast milk.

NAMUH’s mission is to create complete infant formula products substantially comparable to human breast milk, down to the molecular level. Human Milk Oligosaccharides (HMOs) are essential fiber-like nutrients unique to human milk that provide an important energy source to beneficial gut bacteria in infants. Despite being the third most abundant component in human milk, HMOs are currently a small component in infant formulas, if present at all.

Producing HMOs through yeast fermentation

Currently, NAMUH’s proprietary technology provides for a cost-effective source of a family of HMOs via yeast fermentation. NAMUH will leverage Ginkgo’s expertise in yeast strain engineering and fermentation process development through this partnership. Our aim is to enable the production of various HMOs through yeast fermentation and to unlock the possibility of making infant formula nutritionally robust and much closer to human breast milk.

NAMUH plans to leverage Ginkgo’s platform to develop and optimize strains

“Consumer demand for high quality, safe, infant nutrition products is growing, and NAMUH is thrilled to partner with Ginkgo to accelerate our market entry into this rapidly evolving category,” said Dr. Chaeyoung Shin, founder and CEO at NAMUH. “We believe engineering biology is the perfect way to produce crucial nutrients for babies, and together with Ginkgo, we are excited to play a key role in improving how future generations are fed.”

We seek out partners like NAMUH that are using biology to create category-leading products in legacy industries. Countless families around the world rely on infant formula every day, and we are thrilled to be working with NAMUH as they aim to create a healthier, safer formula that parents can depend on.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Celebrating Cronos Group’s First-of-a-Kind CBC Product

Cronos Unveils its New CBC Product, the Spinach FEELZ™ Day Trip Gummies with THC+CBC, Developed on the Ginkgo Platform

We’re so excited to congratulate our customer Cronos – an innovative global cannabinoid company – for launching a CBC-focused product, the Spinach FEELZ™ THC+CBC Day Trip Mango Lime gummies, utilizing our platform for organism design and development.

The Spinach FEELZ™ Day Trip gummies are the first CBC gummy product in Canada and the first of its kind to feature a 3:1 ratio of CBC to THC. The product is currently available in Alberta and British Columbia and will be rolled out to additional provinces over the coming weeks:

  • SPINACH FEELZ™ THC+CBC DAY TRIP GUMMIES: Grab your bag, your friends and get going! A new day’s adventure awaits with Spinach FEELZ™ Day Trip gummies. From sun-up to sun-down, feel at ease and in tune with all the scents, sights, and sounds this glorious world has to offer. These one-of-a-kind THC+CBC gummies are packed with delicious mango-lime flavors and are sure to make for good times with friends. Five sour-then-sweet gummies with 10mg of THC and 30mg of CBC per pack.

What will you grow with Ginkgo?

Sustainable Beauty and Personal Care Products with Sumitomo Chemical

Ginkgo and Sumitomo Chemical aim to create products that will bring significant benefits to consumers by supplying an ingredient that is animal-free and more sustainable than what’s currently on the market.

Ginkgo Bioworks started working with Sumitomo Chemical Co., Ltd, one of Japan’s leading chemical companies, in June 2021 to help significantly increase the production efficiency and sustainability of bio-based commercial products across a broad array of industries. Today, we’re pleased to announce a second collaboration. The new project plans to target a molecule intended to enable the introduction of more sustainable and cost-competitive products in the personal care and cosmetic industries. This molecule is envisioned to augment or replace an ingredient that is currently gathered from animal sources—a process which is not sustainable and also unappealing to many consumers—by producing it via fermentation instead.

What if you could grow ingredients instead of using animal sources?

“The cosmetics industry is demanding more sustainable and cost-competitive beauty and personal care products, as are many others we serve and we see tremendous potential in synthetic biology’s ability to make this possible at a commercial scale,” said Hiroshi Ueda, Executive Vice President of Sumitomo Chemical. “We’re encouraged by the progress of our ongoing first project with Ginkgo, and we believe it’s clear from how well our teams collaborate that we will also be able to find success within additional product areas as well. Through this project, we aim to build our own capability on fermentation production with, active involvement of our new organization SynBio Hub.”

Ginkgo’s platform provides unique advantages thanks to its growing codebase.

Not only is this project a natural fit for Ginkgo’s platform, but it provides the perfect opportunity to leverage and showcase our growing codebase. Ginkgo has prior experience developing a precursor molecule to the one Sumitomo Chemical is currently targeting. The data and experience Ginkgo has on this precursor molecule has significantly accelerated our current program with Sumitomo Chemical, possibly saving Sumitomo Chemical multiple years off its development timeline.

Find the full press release here along with all of the latest news from the Ginkgo team.

Scaling Production of Cultured THCV with Cronos Group

Cronos and Ginkgo Announce Achievement of THCV Equity Milestone

Today, we’re excited to announce an achievement in our partnership with Cronos Group, an innovative global cannabinoid company. Together, we have hit the third target productivity milestone in our partnership to produce eight cultured cannabinoids. Using our platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos’ innovation pipeline and commercialization strategy.

Our partnership with Cronos launched in 2018, with the goal of accessing rare molecules in the cannabis plant to create innovative and differentiated products that would otherwise be cost-prohibitive. The program combines Cronos’ deep understanding of the biological structure and function of cannabinoids with our vast experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture and more.

Producing cultured cannabinoids at industrial scale

“Continuing to hit these productivity milestones in partnership with Ginkgo fuels our innovation pipeline focused on creating borderless products utilizing rare cannabinoids that amplify and differentiate the consumer experience,” said Mike Gorenstein, Chairman, President and CEO of Cronos. “We are excited about the possibilities that THCV is expected to give us and look forward to getting more products with rare cannabinoids into market.”

Working with Cronos to develop innovations in cannabis is an opportunity for us to apply synthetic biology in a way that is helping bring the cannabis industry forward and make a real impact on its market and the customers it serves. The progress we’ve made thus far in our collaboration is a true testament to both the potential of synthetic biology and the world-class teams at Cronos and Ginkgo.

Find the full press release here along with all of the latest news from the Ginkgo team.

What will you grow with Ginkgo?

Synthetic Biology for Climate Action

We believe synthetic biology has an important role to play in addressing climate change.

Climate change is a global threat that requires immediate action. It’s already impacting every single person and living thing on our planet. The best time to address climate change was decades ago; the next best time? Now. So, what are we waiting for? Let’s go grow!

Limiting warming to below 1.5°C will require us to reimagine our industrial landscapes to eliminate emissions and to sequester carbon from the atmosphere. Decarbonizing our energy, materials, chemicals, and food production will require massive shifts in how we make stuff.

We believe that synthetic biology has an important role to play in this climate transition, whether it’s the resilience of ecosystems and communities to a changing climate, the reduction of emissions through circular manufacturing, or the sequestration of carbon through soil, oceanic, lithospheric, or anthropogenic sinks. We believe synthetic biology is going to be one of the enabling technologies for this revolution.

Biology is natively the technology of climate: it makes our air, makes our food, and cleans our water. We believe the ability to engineer biology is ultimately the biggest climate technology in the world.

What are we waiting for? Let’s go grow!

Last week, we hosted a virtual event with several key thought leaders in the world of synthetic biology for climate tech. Over 650 people from the wider synthetic biology and climate tech communities tuned in to share their work and excitement. The panelists discussed carbon fixation and sequestration pathways, manufacturing scale up, and new business models for carbon capture. You can check out the recording of the main stage above or on Ginkgo’s YouTube channel.

Bill Gates recently said that climate tech will create 8 to 10 trillion dollar-scale companies. We believe that at least a few of those will be synthetic biology companies. You may be starting one of those companies right now—we’d love to help you accelerate your climate tech R&D with the tools of our platform. Reach out!

Improving Production Efficiency for Vibrant Food Colors with Phytolon

Phytolon and Ginkgo aim to leverage cell programming to produce vibrant betalain pigments across the full yellow-to-purple spectrum.

Scientists have developed hundreds of artificial food dyes by using the tools of synthetic chemistry to convert petrochemical sources into a wide range of colors. While artificial dyes are visually appealing and cheap to manufacture, many have been banned in food and feed due to health concerns. But now, the tools of synthetic biology offer an opportunity to tap into the vibrant colors of nature to produce more sustainable, yet equally vibrant, colors.

What if you could grow sustainable, vibrant dyes?

As consumers increasingly seek out more sustainable and nature-derived products, the food industry is working to find food colors that have equivalent pigment vibrancy to those found in petrochemical-based dyes but which come from biological sources. Phytolon, a growing startup company making natural food colorants, announced a partnership with Ginkgo today to produce vibrant cultured food colors via synthetic biology.

Phytolon has developed a proprietary process using precision fermentation of certain yeast strains to produce betalain pigments—red and yellow pigments naturally found in plants like beets and cactus fruit. Phytolon and Ginkgo are partnering with the goal of maximizing the production efficiency of purple and yellow betalain-producing strains to enable the creation of colors across the full “yellow-to-purple” spectrum. Under this partnership, Phytolon is leveraging Ginkgo’s ability to engineer biology at scale to work together on the production of these betalain pigments. The project aims to help maximize the business opportunity of Phytolon’s vibrant colors for applications in the food and cosmetics industries.

Synthetic biology helps make it possible to produce nature’s wide range of colors at scale.

“We’re excited to work with Ginkgo to develop natural food colors that can potentially outperform conventional artificial dyes in cost and performance,” says Dr. Tal Zeltzer, co-founder and CTO of Phytolon. “We believe biotechnology makes it possible to produce a wider range of colors than ever before that may outperform current benchmark colorants, and we look forward to building products that may meet and even exceed consumer expectations for healthier, sustainable foods, all while aiming to maintain industry requirements for high quality and cost-efficiency.”

We love enabling growing startups like Phytolon through our platform, using biotechnology to challenge industry norms and attempt to build a fundamentally better product than what’s on the market today. The planet needs new sustainable solutions, and we are excited to partner with Phytolon to support a more sustainable food system.

Find the full press release here along with all of the latest news from the Ginkgo team.

New Platform Venture: Arcaea

The products we traditionally use for personal hygiene and beauty can have large ecological impacts. Many of them use chemicals that are byproducts of fossil fuels or harvest ingredients from threatened or endangered ecosystems. What if we could grow the things that make us feel clean and beautiful, sustainably? Beyond environmental concerns, synthetic biology promises the possibility of products with new functions and a vision of nurturing our personal hygiene and redefining our sense of beauty.

Arcaea, LLC (Ar-kay-uh), incubated on the Ginkgo platform and formed under the name Kalo Ingredients LLC, was launched with the mission to build a new foundation for the beauty industry through expressive biology. The company sees biology as a valuable creative tool for self expression and aims to grow new ingredients and product experiences for beauty through the tools of the synthetic biology ecosystem fostered on the Ginkgo platform. By culturing industry-leading, safe, and sustainable ingredients, Arcaea intends to create a new supply chain for the industry that does not rely on petrochemicals or on harvesting and dwindling natural resources.

By harnessing the power of biology, Arcaea is poised to produce highly sustainable products that can deliver new functionality and performance across skincare, bodycare, haircare, and aesthetics.

The company will be led by Jasmina Aganovic, a chemical and biological engineering graduate from MIT. She brings more than a decade of industry experience translating innovation in beauty through brands and products at various beauty companies, including Fresh and Living Proof and the innovative microbiome beauty company Mother Dirt, which changed the way we think about clean and healthy skin. Jasmina saw the powerful role that biology can play in the cosmetics industry, which prompted her interest in creating tools to better realize its potential. She joined Ginkgo as an Entrepreneur-in-Residence, where she spent the last two years building the foundation for Arcaea.

“Through Arcaea, we see biology as a creative tool that will drive the next generation of products and innovation. We can now access many more molecules on earth ethically and sustainably, and therefore can unlock unlimited and previously unimagined possibilities for beauty,” said Aganovic. “By bringing together new advances in technology with designers, brand builders, and leaders from every point of the supply chain, we can spark a change across the entire ecosystem to create an industry that is reflective of the future we want to see for the industry.”

Arcaea has raised $78 million in Series A funding from a consortium of strategic and financial investors including Cascade Investment L.L.C., Viking Global, CHANEL, Givaudan and Wittington Ventures. This Series A financing round brings together a mix of expertise across the value chain of the industry. It will enable Arcaea to initiate multiple technical programs across key categories in beauty to develop a pipeline of ingredients and brand launches and create a world of previously unimaginable possibilities in beauty, such as: a fragrance that no one on earth has ever smelled before; proteins that can memorize hair styles; contouring through skincare and not just makeup; and biological filters that protect skin from the elements.

“One of the most impactful things we can do at Ginkgo is support entrepreneurs and help them accelerate their timelines to make incredible things happen with biology,” said Jason Kelly, co-founder and CEO of Ginkgo. “We are thrilled to see Arcaea launch and begin its journey to deliver creative solutions to the beauty industry through biology.”

Read the press release here.

New Platform Ventures: Launching Verb Biotics, Ayana Bio

Today we’re announcing the launch of two new companies via the Ferment Consortium: Verb Biotics and Ayana Bio.

Verb—a probiotics innovation company—will focus on identifying and designing new strains of probiotic bacteria with advanced properties for human nutrition, health, and wellness. Ayana plans to support human health and wellness by harnessing bioactive compounds for use as complementary medicine.

Verb Biotics
The probiotics category is a $50B global industry that’s growing rapidly. As awareness and understanding of the human microbiome—the trillions of bacteria that live in and on your body—has grown over the past decade, there’s been tremendous interest in probiotic-enhanced foods, beverages, and supplements. Many existing probiotic products use strains of bacteria common to yogurt and other fermented products, but these strains have a number of challenges including limited shelf life, poor stability, and restrictive metabolic profiles.

Since Ginkgo has significant expertise in the discovery and design of microbes with a wide array of functions, Verb plans to leverage our high-throughput platform to perform sequencing, proteomics and metabolomics analysis, pathway design, cell culturing, and fermentation work in order to improve the design and development of probiotics.

Verb is launching with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment.

Ayana Bio
To address issues ranging from supporting a healthy immune system, to aiding metabolism, to promoting healthy aging, consumers are looking for health products that are complementary to conventional medicine. Two categories of products that offer complementary health products—nutraceuticals and traditional medicines—represent over $400 billion.

The bioactive ingredients that go into products in these categories come from a range of natural sources such as medicinal plants and fungi. However, unsustainable harvesting, variability in the source organisms, and the methods of preparation all contribute to uncertainty around these important molecules and limit the potential for widespread use.

Ayana plans to collaborate with global industry leaders in consumer packaged goods, supplements, specialized nutrition, over-the-counter medicines, and traditional medicines to bring to market standardized bioactives that provide consumers with confidence in quality and reliability. Our cell programming platform will support Ayana’s mission to bring to market high purity, clean and reliable medicinal bioactives in convenient forms.

Ayana is launching with $30 million in Series A funding provided by Viking Global Investors and Cascade Investment.

Ferment Consortium
The Ferment Consortium is a company creation studio that works with Viking Global Investors and Cascade Investment to help incubate, fund, and launch new companies that use cell programming to support human and environmental health and wellbeing. (Psst! If you have a great idea of how to grow the future, Ferment Co would love to hear from you.)

Verb and Ayana join our other Platform Ventures: Joyn Bio, Allonnia, and Motif FoodWorks, which recently raised a $226 million Series B round led by Ontario Teachers Pension Plan and BlackRock.